Europe

A woman who lost her legs after cancer treatment wants to "come home" - but faces being moved 35 miles away.

How Germany sets drug prices and identifying lessons for the United States.

The intergovernmental regional initiatives of collaboration around access to medicines policy are here to stay.

THE UK Government has sought to reassure MSPs that medicine prices will not be affected as part of any future UK-US trade deal after Brexit.

UK's NICE has rejected a number of drugs from coverage recently based on cost-effectiveness criteria.

Well here’s what happened when Germany ignored those warnings.

Disease Burden, Costs and Access to Medicines

Will EU health systems, particularly those with established processes for determining cost-effectiveness, be able to adapt their models to look beyond the immediate upfront costs and take into account longer-term savings associated with gene therapies?

First assessment of a histology-independent drug / studies without control arms.

In America, it's an epidemic. Now new evidence from Public Health England raises concern about the UK's use of prescription opioids.

To match its rhetoric on the NHS, the government has to legally commit to preventing drug-pricing being a part of trade deals.

A ‘ripple effect’ analysis of cancer’s wider impact.

Anticancer Drug Prices and Clinical Outcomes: A cross-sectional study in Italy.

The U.K. will have to offer concessions on granting American drug companies more access to the NHS on terms favourable to the U.S.

A new podcast on how Boston-based pharma company Vertex explained the price of Orkambi and how the discovery of the drug was partly funded by charities and British taxpayers.